Inhibition of angiogenesis by cleaved high molecular weight kininogen (HKa) and HKa domain 5

Current Cancer Drug Targets

Volumn 5, Issue 7, 2005, Pages 519-528

  McCrae, Keith R ^a   Doñate, Fernando ^b   Merkulov, Sergei ^a   Sun, Danyu ^a   Qi, Xiaoping ^a   Shaw, David E ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b D E SHAW RESEARCH   (United States)

Author keywords

Angiogenesis; Bradykinin; Kininogen; Tropomyosin

Indexed keywords

BRADYKININ RECEPTOR; ENDOSTATIN; GLYCOPROTEIN; HISTIDINE; KININOGEN; PROLINE; TROPOMYOSIN;

ANGIOGENESIS; APOPTOSIS; BIOCHEMISTRY; CELL PROLIFERATION; CELL SURFACE; COMPARATIVE STUDY; ENDOTHELIUM CELL; MOLECULAR WEIGHT; PHYSIOLOGY; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; HUMANS; KININOGEN, HIGH-MOLECULAR-WEIGHT; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMA KALLIKREIN;

EID: 27144544180     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800905774574039     Document Type: Review

References (87)

1. Roche e Silva, M.; Beraldo, W. T.; Rosenfeld, G. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am. J. Physiol. 1949, 150, 261-268.
2. Saito, H.; Ratnoff, O. D.; Waldmann, R.; Abraham, J. P. Fitzgerald Trait: Deficiency of a Hitherto Unrecognized Agent, Fitzgerald Factor, Participating in Surface-Mediated Reactions of Clotting, Fibrinolysis, Generation of Kinins, and the Property of Diluted Plasma Enhancing Vascular Permeability (PF/Dil). J. Clin. Invest. 1975, 55, 1082-1090.
3. Colman, R. W.; Bagdasarian, A.; Talamo, R. C.; Scott, C. F.; Seavey, M.; Guimaraes, J. A.; Pierce, J. V.; Kaplan, A. P. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J. Clin. Invest. 1975, 56, 1650-1658.
4. Colman, R. W.; Schmaier, A. H. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997, 90, 3819-3843.
5. Kaplan, A. P.; Joseph, K.; Silverberg, M. Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol. 2002, 109, 195-209.
6. Yarovaya, G. A.; Blokhina, T. B.; Neshkova, E. A. Contact system. New concepts on activation mechanisms and bioregulatory functions. Biochemistry (Moscow) 2002, 67, 13-24.
7. Proud, D.; Pierce, J. V.; Pisano, J. J. Radioimmunoassay of human high molecular weight kininogen in normal and deficient plasmas. J. Lab. Clin. Med. 1980, 95, 693-699.
8. Kaplan, A. P.; Silverberg, M. The coagulation-kinin pathway of human plasma. Blood 1987, 70, 1-15.
9. Schiffman, S.; Mannhalter, C.; Tyner, K. D. Human high molecular weight kininogen. Effects of cleavage by kallikrein on protein structure and procoagulant activity. J. Biol. Chem. 1980, 255, 6433-6438.
10. Mori, K.; Nagasawa, S. Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein. J. Biochem. 1981, 84, 1465-1472.
11. Nishikawa, K.; Shibayama, Y.; Kuna, P.; Calcaterra, E.; Kaplan, A. P.; Reddigari, S. R. Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein. Blood 1992, 80, 1980-1988.
12. Shariat-Madar, Z.; Mahdi, F.; Schmaier, A. H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. 2002, 277, 17962-17969.
13. Herwald, H.; Morgelin, M.; Svensson, H. G.; Sjobring, U. Zinc-dependent conformational changes in domain D5 of high molecular mass kininogen modulate contact activation. Eur. J. Biochem. 2001, 268, 396-404.
14. Weisel, J. W.; Nagaswami, C.; Woodhead, J. L.; DeLa Cadena, R. A.; Page, J. D.; Colman, R. W. The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J. Biol. Chem. 1994, 269, 10100-10106.
15. Jacobsen, S.; Kriz, M. Some data on two purified kininogens from human plasma. Br. J. Pharm. 1967, 29, 25-36.
16. Muller-Esterl, W.; Vohle-Timmerman, B.; Boos, B.; Dittman, M. Purification and properties of human low molecular weight kininogen. Biochim. Biophys. Acta 1982, 106, 145-152.
17. Kitamura, N.; Kitagawa, H.; Fukushima, D.; Takagaki, Y.; Miyata, T.; Nakanishi, S. Structural organization of the human kininogen gene and a model for its evolution. J. Biol. Chem. 1985, 260, 8610-8617.
18. Zhang, J.-C.; Claffey, K.; Sakthivel, R.; Darzynkiewicz, Z.; Shaw, D. E.; Leal, J.; Wang, Y.-C.; Lu, F. M.; McCrae, K. R. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J. 2000, 14, 2589-2600.
19. Merkulov, S.; Komar, A.; McCrae, K. R. Kininogen gene duplication in mice. Blood 2003, 102, 92b.
20. van Iwaarden, F.; deGroot, P. G.; Bouma, B. N. The binding of high molecular weight kininogen to cultured human endothelial cells. J. Biol. Chem. 1988, 263, 4698-4703.
21. Herwald, H.; Hasan, A. A. K.; Godovac-Zimmerman, J.; Schmaier, A. H.; Muller-Esterl, W. Identification of an endothelial cell binding site on kininogen domain D3. J. Biol. Chem. 1995, 270, 14634-14642.
22. Hasan, A. A. K.; Cines, D. B.; Herwald, H.; Schmaier, A. H.; Muller-Esterl, W. Mapping the cell binding site on high molecular weight kininogen domain 5. J. Biol. Chem. 1995, 270, 19256-19261.
23. Hasan, A. A. K.; Cines, D. B.; Zhang, J.; Schmaier, A. H. The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain. J. Biol. Chem. 1994, 269, 31822-31830.
24. Hasan, A. A. K.; Zisman, T.; Schmaier, A. H. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc. Natl. Acad. Sci. USA 1998, 95, 3615-3620.
25. Shariat-Madar, Z.; Mahdi, F.; Schmaier, A. H. Mapping binding domains of kininogens on endothelial cell cytokeratin 1. J. Biol. Chem. 1999, 274, 7137-7145.
26. Joseph, K.; Ghebrehiwet, B.; Peerschke, E. I. B.; Reid, K. B. M.; Kaplan, A. P. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc. Natl. Acad. Sci. USA 1996, 93, 8552-8557.
27. Colman, R. W.; Pixley, R. A.; Najamunnisa, S.; Yan, W.; Wang, J.; Mazar, A.; McCrae, K. R. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J. Clin. Invest. 1997, 100, 1481-1487.
28. Herwald, H.; Dedio, J.; Kellner, R.; Loos, M.; Muller-Esterl, W. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J. Biol. Chem. 1996, 271, 13040-13047.
29. Renne, T.; Dedio, J.; David, G.; Müller-Esterl, W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J. Biol. Chem. 2000, 275, 33688-33696.
30. Shariat-Madar, Z.; Mahdi, F.; Schmaier, A. H. Factor XI assembly and activation on human umbilical vein endothelial cells in culture. Thromb. Haemost. 2001, 85, 544-551.
31. Mahdi, F.; Shariat-Madar, Z.; Schmaier, A. H. The relative priority of prekallikrein and factors XI/XIa assembly on cultured endothelial cells. J. Biol. Chem. 2003, 278, 43983-43990.
32. Lin, Y.; Harris, R. B.; Yan, W. Y.; McCrae, K. R.; Colman, R. W. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood 1997, 90, 690-697.
33. Brown, N. J.; Nadeau, J. H.; Vaughn, D. E. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb. Haemost. 1997, 77, 522-529.
34. Lauer, T.; Kleinbongard, P.; Preik, M.; Rauch, B. H.; Deussen, A.; Feelisch, M.; Strauer, B. E.; Kelm, M. Direct biochemical evidence for eNOS stimulation by bradykinin in the human forearm vasculature. Basic Res. Cardiol. 2003, 98, 84-89.
35. Prado, G. N.; Taylor, L.; Zhou, X.; Ricupero, D.; Mierke, D. F.; Polgar, P. Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. J. Cell. Phys. 2002, 193, 275-286.
36. Marceau, S.; Sabourin, T.; Houle, S.; Fortin, J. P.; Petitclerk, E.; Molinaro, G.; Adam, A. Kinin receptors: functional aspects. Int. Immunopharm. 2002, 2, 1729-1739.
37. Wachtfogel, Y. T.; DeLa Cadena, R. A.; Kunapuli, S. P.; Rick, L.; Miller, M.; Schultze, R. L.; Altieri, D. C.; Edgington, T. S.; Colman, R. W. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J. Biol. Chem. 1994, 269, 19307-19312.
38. Khan, M. M.; Kunapuli, S. P.; Lin, Y.; Majluf-Cruz, A.; De La Cadena, R. A.; Cooper, S. L.; Colman, R. W. Three noncontiguous peptides comprise binding sites on high-molecular-weight kininogen to neutrophils. Am. J. Physiol. 1998, 275, H145-H150.
39. Sheng, N.; Fairbanks, M. B.; Henrickson, R. L.; Canziani, G.; Chaiken, I. M.; Mosser, D. M.; Zhang, H.; Colman, R. W. Cleaved high molecular weight kininogen binds directly to the integrin CD11b/CD18 (Mac-1) and blocks adhesion to fibrinogen and ICAM-1. Blood 2000, 95, 3788-3795.
40. DeLa Cadena, R. A.; Kunapuli, S. P.; Walz, D. A.; Colman, R. W. Expression of thrombospondin 1 on the surface of activated platelets mediates their interaction with the heavy chains of human kininogens through Lys 244-Pro 254. Thromb. Haemost. 1998, 79, 186-194.
41. Joseph, K.; Nakazawa, Y.; Bahou, W. F.; Ghebrehiwet, B.; Kaplan, A. P. Platelet glycoprotein Ib: a zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen. Mol. Med. 1999, 5, 555-563.
42. Renne, T.; Muller-Esterl, W. Cell surface-associated chondroitin sulfate proteoglycans bind contact phase factor H-kininogen. FEBS Lett. 2001, 500, 36-40.
43. DeLa Cadena, R. A.; Colman, R. W. The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface. Protein Sci. 1992, 1, 151-160.
44. Asakura, S.; Hurley, R. W.; Skorstengaard, K.; Ohkubo, I.; Mosher, D. F. Inhibition of cell adhesion by high molecular weight kininogen. J. Cell Biol. 1992, 116, 465-476.
45. Asakura, S.; Yang, W.; Sottile, J.; Zhang, Q.; Jin, Y.-M.; Ohkubo, I.; Sasaki, M.; Matsuda, M.; Hirata, H.; Mosher, D. F. Opposing effects of low and high molecular weight kininogens on cell adhesion. J. Biochem. 1998, 124, 473-484.
46. Chavakis, T.; Kanse, S. M.; Lupu, F.; Hammes, H. P.; Müller-Esterl, W.; Pixley, R. A.; Colman, R. W.; Preissner, K. T. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood 2000, 96, 514-522.
47. Li, C.; Gurewich, V.; Liu, J. N. Urokinase-type plasminogen activator-induced monocyte adhesion is modulated by kininogen, kallikrein, factor XII, and plasminogen. Exp. Cell Res. 1996, 226, 239-242.
48. Voskerician, G.; Anderson, J. M.; Ziats, N. P. High molecular weight kininogen inhibition of endothelial cell function on biomaterials. J. Biomed. Mat. Res. 2000, 51, 1-9.
49. Yung, L. Y.; Lim, F.; Khan, M. M.; Kunapuli, S. P.; Rick, L.; Colman, R. W.; Cooper, S. L. High-molecular-weight kininogen preadsorbed to glass surface markedly reduces neutrophil adhesion. Biomaterials 2000, 21, 405-414.
50. Chavakis, T.; Kanse, S. M.; May, A. E.; Preissner, K. T. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation. Biochem. Soc. Trans. 2002, 30, 168-173.
51. Colman, R. W.; Jameson, B. A.; Lin, Y.; Johnson, D.; Mousa, S. A. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000, 95, 543-550.
52. Ellis, V.; Danø, K. Plasminogen activation by receptor-bound urokinase. Sem. Thromb. Hemost. 1991, 17, 194-200.
53. Ellis, V.; Pyke, C.; Eriksen, J.; Solberg, H.; Danø, K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann. NY Acad. Sci. 1992, 667, 13-31.
54. Blasi, F.; Vassalli, J.-D.; Danø, K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol. 1987, 104, 801-804.
55. Dano, K.; Andreasen, P. A.; Grondahl-Hansen, J.; Kristensen, P.; Neilsen, L. S.; Skrivers, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 1985, 44, 139-146.
56. Wei, Y.; Waltz, D. A.; Rao, N.; Drummond, R. J.; Rosenberg, S.; Chapman, H. A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 1994, 269, 32380-32388.
57. Waltz, D. A.; Chapman, H. A. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 1994, 269, 14746-14750.
58. Kirchheimer, J. C.; Wojta, J.; Christ, G.; Binder, B. R. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J. 1987, 1, 125-128.
59. Tang, H.; Kerins, D. M.; Hao, Q.; Inagami, T.; Vaughn, D. E. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 1998, 275, 18268-18272.
60. Nguyen, D. H. D.; Hussaini, I. M.; Gonias, S. L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 1998, 273, 8502-8507.
61. Nguyen, D. H.; Webb, D. J.; Catling, A. D.; Song, Q.; Dhakephalkar, A.; Weber, M. J.; Ravichandran, K. S.; Gonias, S. L. Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J. Biol. Chem. 2000, 275, 19382-19388.
62. O'Reilly, M. S.; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, R. A.; Moses, M.; Lane, W. S.; Cao, Y.; Sage, E. H.; Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79, 315-328.
63. O'Reilly, M. S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W. S.; Flynn, E.; Birkhead, J. R.; Olsen, B. R.; Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88, 277-285.
64. O'Reilly, M. S.; Pirie-Shepard, S.; Lane, W. S.; Folkman, J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999, 285, 1926-1928.
65. Zhang, J. C.; Qi, X.; Juarez, J.; Plunkett, M.; Donate, F.; Sakthivel, R.; Mazar, A. P.; McCrae, K. R. Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides. Can. J. Physiol. Pharmacol. 2002, 80, 85-90.
66. Ferriera, M. A.; Andrade, S. P.; Pesquero, S. L.; Feitosa, M. H.; Oliveria, G. M.; Rogana, E.; Noguiera, J. C.; Beraldo, W. T. Kallikrein-kinin system in the angiogenesis. Agents Actions (Suppl.) 1992, 35(Part 2), 165-174.
67. Morbidelli, L.; Parenti, A.; Donnini, S.; Granger, H. J.; Ledda, F.; Ziehe, M. Differential contribution of bradykinin receptors in angiogenesis. Adv. Exp. Med. Biol. 2000, 476, 117-128.
68. Hayashi, I.; Amano, H.; Yoshida, S.; Kamata, K.; Kamata, M.; Inukai, M.; Fujita, T.; Kumagai, Y.; Furudate, S.; Majima, M. Suppressed angiogenesis in kininogen-deficiencies. Lab. Invest. 2002, 52, 871-880.
69. Ishihara, K.; Kamata, M.; Hayashi, I.; Yamashina, S.; Majima, M. Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int. Immunopharm. 2002, 2, 499-509.
70. Ishihara, K.; Hayashi, I.; Yamashina, S.; Majima, M. A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors. Jap. J. Pharmacol. 2001, 87, 318-326.
71. Parenti, A.; Morbidelli, L.; Ledda, F.; Granger, H. J.; Ziche, M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 2001, 15, 1487-1489.
72. Plendl, J.; Snyman, C.; Naidoo, S.; Sawant, S.; Mahabeer, R.; Bhoola, K. D. Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol. Chem. 2000, 381, 1103-1115.
73. Thuringer, D.; Maulon, L.; Frelin, C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J. Biol. Chem. 2002, 277, 2028-2032.
74. Miura, S.; Matsuo, Y.; Saku, K. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 2003, 41, 1118-1123.
75. Silvestre, J. S.; Bergaya, S.; Tamarat, R.; Duriez, M.; Boulanger, C. M.; Levy, B. I. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ. Res. 2001, 89, 678-683.
76. Oh-ishi, S.; Hayashi, I.; Hosiko, S.; Makabe, O. Molecular mechanism of kininogen deficiency in brown Norway Katholiek rats. Brazil. J. Biol. Res. 1994, 27, 1803-1815.
77. Colman, R. W. Inhibition of angiogenesis by a monoclonal antibody to kininogen as well as by kininostatin which block proangiogenic high molecular weight kininogen. Int. Immunopharm. 2002, 2, 1887-1894.
78. Colman, R. W.; Pixley, R. A.; Sainz, I. M.; Song, J. S.; Isordia-Salas, I.; Muhamed, S. N.; Powell, J. A. Jr.; Mousa, S. A. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J. Thromb. Haemost. 2003, 1, 164-170.
79. Chavakis, T.; Pixley, R. A.; Isordia-Salas, I.; Colman, R. W.; Preissner, K. T. A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function. J. Biol. Chem. 2002, 277, 32677-32682.
80. Kamiyama, F.; Maeda, T.; Yamane, T.; Yao-Hua, L.; Ogukobo, O.; Otsuka, T.; Ueyama, H.; Takahashi, S.; Ohkubo, I.; Matsui, N. Inhibition of vitronectin-mediated haptotaxis and haptoinvasion of MG-63 cells by domain 5 (D5(H)) of human high-molecular-weight kininogen and identification of a minimal amino acid sequence. Biochem. Biophys. Res. Comm. 2001, 288, 975-980.
81. Bosman, S. T.; Stamenkovic, I. Functional structure and composition of the extracellular matrix. J. Pathol. 2003, 200, 423-428.
82. Stromblad, S.; Cheresh, D. A. Cell adhesion and angiogenesis. Trends Cell Biol. 1996, 6, 462-468.
83. Kawasaki, M.; Maeda, T.; Hanasawa, K.; Ohkubo, I.; Tani, T. Effect of His-Gly-Lys motif derived from domain 5 of high molecular weight kininogen on suppression of cancer metastasis both in vitro and in vivo. J. Biol. Chem. 2003, 275, 49301-49307.
84. Guo, Y. L.; Wang, S.; Cao, D. J.; Colman, R. W. Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. J. Cell. Biochem. 2003, 89, 622-632.
85. Wang, S.; Hasham, M. G.; Isordia-Salas, I.; Tsygankov, A.; Colman, R. W.; Guo, Y. L. Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen. Am. J. Physiol. Heart Circ. Physiol. 2003, 284, H1917-H1923.
86. Zhang, J. C.; Donate, F.; Qi, X.; Ziats, N. P.; Juarez, J. C.; Mazar, A. P.; Pang, Y. P.; McCrae, K. R. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc. Natl. Acad. Sci. USA 2002, 99, 12224-12229.
87. MacDonald, N. J.; Shivers, W. Y.; Narum, D. L.; Plum, S. M.; Wingard, J. N.; Fuhrmann, S. R.; Liang, H.; Holland-Linn, J.; Tom Chen, D. H.; Sim, B. K. L. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J. Biol. Chem. 2001, 276, 25190-25196.